You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
南京醫藥(600713.SH)2019年度淨利潤升31.26%至3.47億元 擬10派1元
格隆匯 03-30 20:18

格隆匯3月30日丨南京醫藥(600713.SH)披露2019年年度報告,實現營業收入371.56億元,同比增長18.70%;歸屬於上市公司股東的淨利潤3.47億元,同比增長31.26%;歸屬於上市公司股東的扣除非經常性損益的淨利潤2.83億元,同比增長16.02%;基本每股收益0.333元,擬每10股派發現金紅利1元(含税)。

公司屬於服務大健康產業的藥品流通行業,主要從事藥品流通業務,即從上游醫藥生產企業採購產品,然後再批發給下游的經銷商、醫院、藥店等或通過零售直接銷售給消費者。公司市場覆蓋蘇皖閩鄂等地及雲川部分地區,業務覆蓋近70個城市,在區域市場積累了豐富的醫藥商業運作經驗、資源和品牌知名度,業務規模位居國內醫藥流通業第八位。

公司零售業務由社會零售藥房和特藥藥店兩部分組成,零售門店合計510餘家。

社會零售藥房業務終端分佈在蘇皖閩等三省八市,主要通過直營店和部分加盟店連鎖形式銷售處方藥、非處方藥及醫療器械、相關健康產品等。公司擁有百信藥房等九家區域品牌連鎖機構,零售業務管理平台下的零售門店總數380多家,其中定點醫保資質門店佔比超90%、百年老字號藥店6家。公司零售業務以客户健康需求為導向,強化藥學服務水平,切實做好會員管理與服務,探索多模式醫藥零售業務,打造京醫藥健康管理零售品牌。結合互聯網+”發展趨勢,在醫藥電商、會員健康管理、慢病管理等方面積極佈局並探索實踐。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account